An Italian contract seeks new NGS systems, reagents and software to boost genomic profiling in oncology and hereditary disease, signalling wider EU momentum.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
An Italian hospital trust has put out a contract notice for a comprehensive next generation sequencing upgrade. The Supply of NGS Systems and Reagents from ASST Spedali Civili di Brescia covers analytical systems, sequencers, reagents and bioinformatics software to support genomic profiling and molecular characterisation in oncology and hereditary diseases. Published in October 2025, it reflects a steady move to embed genome-led diagnostics in routine care.
The notice sets out plans to procure an integrated NGS capability, combining instruments with the reagents and software needed to produce and interpret genomic data. The emphasis on oncology and inherited conditions points to two high-impact use cases: informing targeted cancer treatments and clarifying genetic risks in families.
Bundling hardware, consumables and bioinformatics is now common across European buyers. It can simplify validation and shorten time to service by aligning the sequencing chemistry with data analysis pipelines. In practical terms, the package here is designed to deliver end‑to‑end workflows, from sample preparation through to variant calling and reporting, within a hospital environment.
Key components flagged by the notice include:
Italy’s public sector has been building similar capacity over the past three years. In June 2022, the Azienda Ospedaliera di Perugia launched a five‑year, three‑lot rental supply for a molecular diagnostic system dedicated to genomic profiling of solid and haematological tumours (procurement).
That push continued in October 2022 at Azienda Ospedaliera S.Croce e Carle, which split an NGS expansion into three lots covering a general NGS system, HLA typing, and mutation analysis in solid tumours, with five‑year base amounts of €900,000, €1.1 million and €850,000 respectively (contract notice).
In November 2022, IRCCS Policlinico Ospedale San Martino went to market for a complete NGS system capable of analysing DNA and RNA from solid tumours, liquid biopsies and germline samples, setting a three‑year base amount of €2.85 million (tender).
Hospitals are also pairing NGS with complementary methods. In August 2024, A.O. San Giovanni Addolorata sought reagents and instrumentation for real‑time digital PCR alongside NGS for oncology and gene panels (notice). In April 2025, Fondazione IRCCS Ca' Granda – Ospedale Maggiore Policlinico went out for systems to perform target resequencing of clinical exomes and panels, including reagents, calibrators, controls and interpretation software (procurement).
The pipeline is not limited to cancer. In October 2025, the Università degli studi di Bari sought reagents and services for nucleic acid extraction and NGS sequencing, with assistance for sequencers in a genetic laboratory focused on neurodegenerative diseases (tender).
Technical baselines emerging from recent Italian notices show how buyers define throughput, read length and clinical scope. In May 2023, ASST Fatebenefratelli Sacco published a prior information notice for a 36‑month “supply in service” NGS system, possibly renewable for another 36 months, with minimum features including:
The same notice bundled a detailed kit list covering HIV‑1 drug resistance and tropism, HCV and HBV resistance and genotyping, full‑genome SARS‑CoV‑2 sequencing, a respiratory virus panel, a metagenomic kit, and pathogen library prep from low‑input DNA. It also called for analysis software and routine and emergency maintenance over the term (PIN). That breadth underlines NGS’s role in both clinical virology and oncology.
Several notices go beyond the sequencer to lock in the workflow. In June 2023, the Università degli Studi di Torino sought an integrated platform comprising an automatic nucleic‑acid extractor, automated electrophoresis for quality control, and a high‑productivity massive parallel sequencer for a public health genomics project (tender).
Targeted oncology panels remain a priority too. In October 2024, IRCCS Fondazione Pascale advertised an integrated NGS system to analyse 50 genes and more than 100 MSI loci, bundling reagents and instrumentation (notice). And in April 2025, the Azienda Socio Sanitaria Territoriale di Mantova specified reagents dedicated to the Illumina MiSeq, alongside a real‑time PCR system for somatic genomic assays (contract notice), indicating how some buyers tie consumables to known installed bases.
Public buyers are mixing capital purchase, rental and outright service provision. In December 2023, AOUI launched a five‑year procurement, with possible renewal, for first‑ and second‑level sequencing systems with rental instrumentation, reagents and consumables across four lots, including NGS for cystic fibrosis and rare skeletal diseases and Sanger sequencing (tender). In November 2023, Azienda Ospedaliero‑Universitaria Sant’Andrea signalled a 12‑month rental acquisition of an NGS machine‑reagent system (PIN), while in May 2025 I.F.O. sought rental and assistance for a high‑throughput automated NGS platform, including reagents and nucleic‑acid purification, to be awarded on a quality‑price basis (notice).
Others are outsourcing testing. In October 2024, ARNAS G. Brotzu moved to procure molecular oncology testing services using NGS for its genetics and genomics laboratory (procurement). Beyond Italy, a November 2024 notice from Medical University – Plovdiv outlined three lots of next‑generation sequencing services for cancer, including targeted analysis of more than 400 genes and whole‑exome sequencing from tumour DNA (tender).
Procurement patterns elsewhere in the EU reinforce the trend. In December 2024, AGEPS in France sought the supply, delivery, installation and commissioning of second‑generation short‑read sequencers, explicitly excluding libraries and bioinformatics from scope (contract notice). In May 2024, the Commissariat à l’énergie atomique et aux énergies alternatives ran an open procedure for a medium‑throughput second‑generation sequencer with accessories and programs included (tender). And in July 2025, a notice set out a plan to procure a DNA analysis system using NGS and associated reagents for health purposes (notice).
The Brescia contract points to continued investment in hospital‑based genomics, with instruments, consumables and bioinformatics treated as a single operational package. Recent notices suggest buyers will keep mixing purchase, rental and service models, and will specify platforms for both broad diagnostic coverage and targeted panels. Watch for more procurements that combine NGS with arrays and PCR, and for explicit inclusion of interpretation software and maintenance, as seen in 2022–2025 notices across Italy and the wider EU.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.